Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

13.22 -0.29 (-2.15%)
Delayed Quote Updated: 12:28 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Earnings Scheduled For November 26, 2024 ↗
 
Via Benzinga
News headline image
Earnings Preview: MediWound ↗
 
Via Benzinga
News headline image
MediWound to Report Third Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Preview: MediWound's Earnings ↗
 
Via Benzinga
News headline image
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024 ↗
MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
Via Benzinga
News headline image
US Stocks Mixed; Jobs Figures Top Estimates For June ↗
 
Via Benzinga
News headline image
Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket ↗
Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million... 
Via Benzinga
News headline image
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024 ↗
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
News headline image
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023 ↗
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 21, 2024 ↗
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
News headline image
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients... 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Participate in Two Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.